Navigation Links
CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
Date:2/21/2008

evation Acute Coronary Syndrome; Poster, Monday, March 31, 2008, 3:00 p.m. CST

Efficacy and Safety of Ranolazine in Chronic Angina: Observations from the Randomized, Double-blind, Placebo-controlled MERLIN-TIMI 36 Trial; Poster, Tuesday, April 1, 2008, 11:00 a.m. CST

Regadenoson

Heart Rate Response to Adenosine and Regadenoson in Diabetes Mellitus: A Marker of Autonomic Cardiac Neuropathy; Poster, Tuesday, April 1, 2008, 11:30 a.m. CST

Additional information regarding the ACC 57th Annual Scientific Sessions can be accessed at http://acc08.acc.org/Pages/default.aspx.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT- 6883, which is being developed for potential treatment of cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking sta
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... San Francisco, CA (PRWEB) July 24, 2014 ... Wednesday to be semi-finalists in Livestrong’s Big C Competition. ... Decisive Health are each headed to the semi-final round. ... in Livestrong’s exclusive three-month accelerator program, complete with mentoring ... country. , As part of the angelMD commitment ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
(Date:7/24/2014)... 24, 2014 1000 balances – 4 ... on customers’ weighing needs and expertly narrows down the ... balances, scales or even terminals. , First, select ... weight (or select readability instead) and define the accuracy ... selection criteria narrows down the list to models that ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Draper ... , is proud to announce that for 6 ... different countries will converge on the Draper University ... an intensive, experiential program focused on entrepreneurship, building ... selective school, currently running its sixth cohort, continues ...
Breaking Biology Technology:3 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3
... and AALST , Belgium, AHMEDABAD, India and ... genae associates,Cardiovascular Center Aalst and J.B. Dahm, ... Core Laboratories joint venture, called imaeon., ... of medical images,analysis for clinical research projects, ...
... EDMONTON, Oct. 6 /PRNewswire-FirstCall/ - BioMS Medical ... of multiple sclerosis (MS), today,announced that the independent ... II MINDSET-01 trial of dirucotide (MBP8298) in patients,with ... recommended,that the trial continue as per the protocol., ...
... focus on a new dietary supplement resulting from years of, ... ... Del-Immune V, BOULDER, Colo., Oct. 6 On ... regulatory,cytokines Del-Immune V(R) induction and its impact on cytotoxicity of,natural killer cells" ...
Cached Biology Technology:Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm 2BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2EUPROBIO 2008 Presentation to Highlight Latest Immune Research 2
(Date:7/25/2014)... novel study shows that the age girls reach puberty is ... depending on which parent contributes the gene. This is ... of development after birth and details of this study were ... of the first period, known as menarche, is a marker ... shows that the onset of menses varies between girls, is ...
(Date:7/25/2014)... researchers have detected an unknown interaction between microorganisms and ... into a droplet of salt water and is left ... create biomineralogical biosaline 3D morphologically complex formations, where they ... revived. The discovery was made by chance with a ... Astrobiology journal and may help to find ...
(Date:7/24/2014)... how wildlife loss leads to conflict among people around ... Conservation Society (WCS) Health & Ecosystems: Analysis of Linkages ... interdisciplinary approach to tackle global biodiversity decline. , The ... the world,s people and provides protein for more than ... as no surprise that today,s unprecedented loss of wildlife, ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Bacteria manipulate salt to build shelters to hibernate 2New study draws links between wildlife loss and social conflicts 2
... co-authored by University of Florida researchers provides details on the ... as warm summer waters attract more people to the ocean. ... print edition of Pacific Science warns that swimmers ... be considered prey. The sharks feed near the ...
... filled an important gap in the study of tunicate evolution ... free-swimming types of tunicates. Their study was featured on the ... Plankton Research . Tunicates are a phylum of animals ... called a tunic, from which the name derives. ...
... 2011 Jerusalem, Israel The Israeli Chairmanship of EUREKA, ... innovation, has released new data from a report conducted ... firm Applied Economics Ltd., to mark the completion of ... study presents the proven impact of EUREKA on companies ...
Cached Biology News:New study documents first cookiecutter shark attack on a live human 2New study documents first cookiecutter shark attack on a live human 3Woods Hole Oceanographic Institution study sheds light on tunicate evolution 2Is governmental investment in industrial R&D paying off? 2Is governmental investment in industrial R&D paying off? 3